MAT & MATE Acts
Updates to Buprenorphine Prescribing & Substance Use Training from the Consolidated Appropriations Act (CAA), 2023
On December 29, 2022, President Biden signed the fiscal year 2023 omnibus, passing the Mainstreaming Addiction Treatment (MAT) and Medication Access and Training Expansion (MATE) Acts. These bills were passed to expand access to buprenorphine for the treatment of opioid use disorder, and normalize and enhance substance use care across healthcare settings.
DACS is monitoring guidance from state and federal agencies closely and will update this page when more information becomes available. The resources on this page offer information about the omnibus, the bills, and the implications for healthcare providers and programs.
Primary guidance about the MAT and MATE Acts:
SAMHSA: Removal of DATA Waiver (X-Waiver) Requirement
DEA: Letter to DEA Registrants
ASAM Webinar recording and resources: Addiction Policy and the Consolidated Appropriations Act
DCHA Podcast: Policy Change: 2023 Omnibus & MAT Act
MAT Act: Removes the waiver requirement to prescribe buprenorphine for opioid use disorder
With this provision, and effective immediately, SAMHSA will no longer be accepting NOIs (waiver applications). All practitioners who have a current DEA registration that includes Schedule III authority, may now prescribe buprenorphine for Opioid Use Disorder in their practice if permitted by applicable state law and SAMHSA encourages them to do so. - SAMHSA update
- Legislation on Sec 1262, page 3128: FY 2023 Omnibus (Full)
- MAT Act: Summary of Solutions Included in the FY 2023 Omnibus – End Substance Use Disorder
- MAT Act Signed Into Law, NABP Applauds Benefits for Overdose Prevention and Recovery Support – National Association of Boards of Pharmacy
MATE Act: Requires prescribers of controlled substances to complete an 8-hour SUD training upon renewing or receiving their DEA license
SAMHSA and DEA are actively working on implementation of a separate provision of the Omnibus related to training requirements for DEA registration that becomes effective in June 2023. Please continue to check this webpage for further updates and guidance. - SAMHSA update
- Legislation on Sec. 1263, page 3132: Requiring Prescribers of Controlled Substances to Complete Training
- Overview: Shatterproof Applauds the Passage of the MATE Act to Expand Addiction Education – Business Wire article
Resources, articles, and statments about the MAT and MATE Acts
President Signs Bipartisan Measure to Improve Addiction Treatment – Pew Trusts article
Policies Governing Buprenorphine for Opioid Use Disorder – ASAM update
“Healthcare practitioners should also be aware of applicable state laws or regulations that may still be in effect regarding the prescribing and dispensing of buprenorphine for SUD treatment and will need to seek further guidance from their state officials considering the impact of this federal reform in their state.”
Consolidated Appropriations Act 2023
Statement from President Joe Biden on Passage of the Bipartisan Year-End Omnibus – White House Press release
Fiscal Year 2023 Omnibus Appropriations Bill: Highlights – Senate Appropriations Committee
Behavioral health legislation in the omnibus
Full omnibus as well as highlight behavioral health legislation – National Council for Mental Wellbeing
Consolidated Appropriations Act, 2023 Detailed Summary - Partnership to End Addiction